Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals

Abstract. With the stated aim of scanning small regions of interest in mice, several high-resolution positron emission tomographic (PET) systems are presently under development. Some, however, have low sensitivity and require high doses of radioactivity to achieve count statistics adequate to reconstruct small volumes. Using in vivo dissociation constants for three carbon-11 labelled ligands previously measured in rat brain, the present paper utilises simple saturation kinetics to estimate the limits on radioactivity and specific activity, to minimise the degree of receptor occupancy and achieve maximal specific binding of the radioligand. The extent of the problem is exemplified by considering a high-affinity ligand (dissociation constant in vitro ∼0.1 nM; in vivo ∼5 nmol/kg i.v. injected dose), where routinely produced levels of specific activity (∼100 MBq/nmol) would limit the activity injected into mice to ∼0.1 MBq for a 1% receptor occupancy. If, as is feasible, the new generation of high resolution PET systems requires an injected activity >10 MBq, then a >100-fold increase in specific activity would be needed for tracer kinetics to hold. The paper highlights the need to consider realistically achievable goals if high-resolution PET is to be accepted as a viable methodology to acquire pharmacologically and physiologically accurate ligand-receptor binding data in mice.

[1]  T J Spinks,et al.  Three-dimensional performance of a small-diameter positron emission tomograph. , 1997, Physics in medicine and biology.

[2]  G. Sedvall,et al.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.

[3]  G. Brownell,et al.  Cocaine congeners as PET imaging probes for dopamine terminals. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  M. Hamon,et al.  The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. , 1995, European journal of pharmacology.

[5]  P A Sargent,et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.

[6]  M. Kuhar,et al.  In vivo labeling of cocaine binding sites on dopamine transporters with [3H]WIN 35,428. , 1991, The Journal of pharmacology and experimental therapeutics.

[7]  S O Ogren,et al.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.

[8]  A A Lammertsma,et al.  Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.

[9]  S H Snyder,et al.  Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease , 1993, Annals of neurology.

[10]  D J Brooks,et al.  Effect of L‐dopa and 6‐hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET , 1995, Synapse.

[11]  L. Farde,et al.  PET analysis of central [11 C]raclopride binding in healthy young adults and schizophrenic patients—reliability and age effects , 1992 .

[12]  Adriaan A. Lammertsma,et al.  In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner , 1997, Journal of Neuroscience Methods.